Pharminent

AstraZeneca licenses inflammatory disease candidate to Allergan

LONDON (Reuters) – Britain’s AstraZeneca said it had licensed a potential medicine for inflammatory diseases to Allergan for an upfront payment of $250 million and potential additional payments of up to $1.27 billion.

http://www.reuters.com/article/us-astrazeneca-allergan-inflammatory-dru-idUSKCN1230FL

Filed under: Inflammatory